Market Overview

Nomura Downgrades Valeant, Says It's Been 'Humbled'


Nomura’s Shibani Malhotra downgraded Valeant Pharmaceuticals Intl Inc (NYSE: VRX) from Buy to Neutral, while slashing the price target from $175 to $60. She commented, “We have lost conviction in Valeant.”

The company has announced a larger reduction in its 2016 than was anticipated. “We admit upfront, we have been humbled by our stock call on VRX, which we have defended despite the continuing spate of bad news, as we believed that despite the noise surrounding the company, much of the fundamental businesses had been performing well,” analyst Shibani Malhotra wrote.

The new target price does represent potential upside of 79.1 percent. The analyst mentioned, however, that the company’s shares are unlikely to outperform the market in the near term. She added that confidence had been lost in management’s ability to understand the company’s business and offer a guidance that is reliable.

Latest Ratings for VRX

Jun 2018TD SecuritiesDowngradesBuyHold
Jun 2018BarclaysUpgradesEqual-WeightOverweight
May 2018MizuhoUpgradesNeutralBuy

View More Analyst Ratings for VRX
View the Latest Analyst Ratings

Posted-In: Nomura Shibani MalhotraAnalyst Color Downgrades Price Target Analyst Ratings


Related Articles (VRX)

View Comments and Join the Discussion!

Latest Ratings

GRPNMorgan StanleyMaintains1.5
HMSYCantor FitzgeraldReiterates33.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at